Kassack MU - Search Results

1

Biased inhibition by a suramin analogue of A1-adenosine receptor/G protein coupling in fused receptor/G protein tandems: the A1-adenosine receptor is predominantly coupled to Goalpha in human brain.

Kudlacek O, Waldhoer M, Kassack MU, Nickel P, Salmi JI, Freissmuth M, Nanoff C. Kudlacek O, et al. Among authors: kassack mu. Naunyn Schmiedebergs Arch Pharmacol. 2002 Jan;365(1):8-16. doi: 10.1007/s00210-001-0493-y. Epub 2001 Nov 7. Naunyn Schmiedebergs Arch Pharmacol. 2002. PMID: 11862328

2

The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range.

Horner S, Menke K, Hildebrandt C, Kassack MU, Nickel P, Ullmann H, Mahaut-Smith MP, Lambrecht G. Horner S, et al. Among authors: kassack mu. Naunyn Schmiedebergs Arch Pharmacol. 2005 Jul;372(1):1-13. doi: 10.1007/s00210-005-1085-z. Epub 2005 Sep 13. Naunyn Schmiedebergs Arch Pharmacol. 2005. PMID: 16158305

3

Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists.

Lambrecht G, Braun K, Damer M, Ganso M, Hildebrandt C, Ullmann H, Kassack MU, Nickel P. Lambrecht G, et al. Among authors: kassack mu. Curr Pharm Des. 2002;8(26):2371-99. doi: 10.2174/1381612023392973. Curr Pharm Des. 2002. PMID: 12369951 Review.

4

Suramin and suramin analogs activate skeletal muscle ryanodine receptor via a calmodulin binding site.

Klinger M, Freissmuth M, Nickel P, Stäbler-Schwarzbart M, Kassack M, Suko J, Hohenegger M. Klinger M, et al. Mol Pharmacol. 1999 Mar;55(3):462-72. Mol Pharmacol. 1999. PMID: 10051529

5

NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors.

Braun K, Rettinger J, Ganso M, Kassack M, Hildebrandt C, Ullmann H, Nickel P, Schmalzing G, Lambrecht G. Braun K, et al. Naunyn Schmiedebergs Arch Pharmacol. 2001 Sep;364(3):285-90. doi: 10.1007/s002100100463. Naunyn Schmiedebergs Arch Pharmacol. 2001. PMID: 11521173

6

NF449, a novel picomolar potency antagonist at human P2X1 receptors.

Hülsmann M, Nickel P, Kassack M, Schmalzing G, Lambrecht G, Markwardt F. Hülsmann M, et al. Eur J Pharmacol. 2003 May 30;470(1-2):1-7. doi: 10.1016/s0014-2999(03)01761-8. Eur J Pharmacol. 2003. PMID: 12787824

7

Profiling at recombinant homomeric and heteromeric rat P2X receptors identifies the suramin analogue NF449 as a highly potent P2X1 receptor antagonist.

Rettinger J, Braun K, Hochmann H, Kassack MU, Ullmann H, Nickel P, Schmalzing G, Lambrecht G. Rettinger J, et al. Among authors: kassack mu. Neuropharmacology. 2005 Mar;48(3):461-8. doi: 10.1016/j.neuropharm.2004.11.003. Neuropharmacology. 2005. PMID: 15721178

8

Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases.

McCain DF, Wu L, Nickel P, Kassack MU, Kreimeyer A, Gagliardi A, Collins DC, Zhang ZY. McCain DF, et al. Among authors: kassack mu. J Biol Chem. 2004 Apr 9;279(15):14713-25. doi: 10.1074/jbc.M312488200. Epub 2004 Jan 20. J Biol Chem. 2004. PMID: 14734566 Free article.

9

Stability of suramin in aqueous solution; possible implications for the search for suramin metabolites in patients.

Kassack M, Nickel P. Kassack M, et al. Arch Pharm (Weinheim). 1996 May;329(5):225-8. doi: 10.1002/ardp.19963290502. Arch Pharm (Weinheim). 1996. PMID: 8779632

10

Antiangiogenic and antiproliferative activity of suramin analogues.

Gagliardi AR, Kassack M, Kreimeyer A, Muller G, Nickel P, Collins DC. Gagliardi AR, et al. Cancer Chemother Pharmacol. 1998;41(2):117-24. doi: 10.1007/s002800050717. Cancer Chemother Pharmacol. 1998. PMID: 9443624

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

138 results

Search Page

Filters